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Effective delivery of Complex Innovative Design (CID) cancer
trials—A consensus statement
Sarah P. Blagden1, Lucinda Billingham2, Louise C. Brown3, Sean W. Buckland4, Alison M. Cooper5, Stephanie Ellis6, Wendy Fisher7,
Helen Hughes8, Debbie A. Keatley9, Francois M. Maignen10, Alex Morozov11, Will Navaie6, Sarah Pearson12, Abeer Shaaban13,
Kirsty Wydenbach14, Pamela R. Kearns2,15, on behalf of the Experimental Cancer Medicine Centres (ECMC) CID trials working group
The traditional cancer drug development pathway is increasingly being superseded by trials that address multiple clinical
questions. These are collectively termed Complex Innovative Design (CID) trials. CID trials not only assess the safety and toxicity of
novel anticancer medicines but also their efficacy in biomarker-selected patients, specific cancer cohorts or in combination with
other agents. They can be adapted to include new cohorts and test additional agents within a single protocol. Whilst CID trials can
speed up the traditional route to drug licencing, they can be challenging to design, conduct and interpret. The Experimental Cancer
Medicine Centres (ECMC) network, funded by the National Institute for Health Research (NIHR), Cancer Research UK (CRUK) and the
Health Boards of Wales, Northern Ireland and Scotland, formed a working group with relevant stakeholders from clinical trials units,
the pharmaceutical industry, funding bodies, regulators and patients to identify the main challenges of CID trials. The working
group generated ten consensus recommendations. These aim to improve the conduct, quality and acceptability of oncology CID
trials in clinical research and, importantly, to expedite the process by which effective treatments can reach cancer patients.
British Journal of Cancer https://doi.org/10.1038/s41416-019-0653-9
BACKGROUND
Cancer is diagnosed in around 18 million people every year
worldwide, and 9.6 million die of the disease.1 With unhealthy
lifestyles and increased longevity, the annual incidence of cancer
is set to rise to 29.5 million in 2040. However, for the majority of
these cancers, effective treatment remains an unmet medical
need.2 Recent discoveries in cancer biology and especially
immuno-oncology have led to an expansion in the number of
new cancer therapies entering clinical development but, frustrat-
ingly, the traditional drug development pathway is slow with
novel agents taking an average of 12 years to reach clinical
practice.3 This has generated a “bottleneck” of agents and
combinations awaiting clinical evaluation.
To overcome this, the traditional pathway is increasingly being
overturned in favour of innovative and efficient trial designs that
combine multiple clinical questions within a single study. The term
“Complex Innovative Design” (CID) trial here is used to describe
them. This includes trials that incorporate several drug develop-
ment phases (such as seamless Phase 1–2 or Phase 2–3 studies);
those with adaptive features (such as using dose–response
modelling);4 those that evaluate multiple treatments for one
indication, one treatment for multiple indications; or those that
incorporate multiple treatments and multiple indications within
a single “master” protocol.5,6 Examples of these trials are shown
in Table 1.
So far, the main CID trials to have been conducted are “master
protocol” trials that incorporate molecular biomarkers to define
patient cohorts. These include “basket” and “umbrella’ designs”.7
Unlike conventional clinical trials in which patients are recruited
by their tumour of origin, patients enrolled in basket trials have
different tumour types, but all have a common molecular
characteristic (a biomarker) relevant to the treatment under
investigation. By contrast, in umbrella trials, patients with a single-
tumour type are stratified into multiple cohorts based on
molecular markers defining each treatment arm. These stratifica-
tions allow parallel comparison of therapy/ies for an individual
disease (or biomarker cohort) or enable overall assessment via a
single stratified analysis. In addition, treatments and patient
cohorts can be added or discontinued whilst the trial is ongoing.
CID trials have long been recognised by regulators and other
agencies as important tools in drug development. In 2007, the
European Medicines Agency (EMA) provided guidance on
the introduction of adaptive measures in trials and, in 2011, on
risk-based quality management.8,9 Within their 2017 Life Sciences
Industrial Strategy, the UK Government committed investment
towards clinical trials that incorporate “novel methodology” and
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their subsequent Sector Deal 2 was agreed, in partnership with
industry, to fund the research infrastructure to deliver them.10,11
Outside Europe, the US Food and Drug Administration (FDA)
released draft guidance around risk-based monitoring in 2013 and
around master protocols and adaptive designs in 2018. The FDA
have also launched a pilot programme to support CID trials that
accelerate drug development in areas of unmet need.12,13
One of the earliest examples of a CID trial was the international
PROFILE 1001 non-small cell lung cancer (NSCLC) study designed
to investigate crizotinib, a targeted inhibitor of the tyrosine kinase
cMET.14 As data emerged that rearrangements of the Anaplastic
Lymphoma Receptor Tyrosine kinase (ALK) gene were present in a
small subset of NSCLC patients, new molecularly defined study
cohorts were added to capture this population. As a result, EU
Marketing Authorisation was obtained for crizotinib just 5 years
after the discovery of the EML4-ALK fusion gene.15,16 Examples of
other CID trials are shown in Table 1.
AIMS
Drawing on the experiences of multiple stakeholders involved in
CID trials, we described the pathway and hurdles encountered
when conducting these trials and formulated consensus recom-
mendations to navigate them. Whilst we used the UK clinical
research infrastructure as a test case, the experiences are
applicable to all international stakeholders involved in CID trials
and highlight their increasing importance in both academic and
commercial development. Although the focus of this review is
oncology based, its recommendations are applicable to other
disease areas.
Method: evaluating the landscape and formulating the consensus
recommendations
The UK hosts a networked infrastructure of adult and paediatric
early-phase trial centres; the Experimental Cancer Medicine
Centres (ECMC) network.17 Each centre exists as a partnership
between National Health Service (NHS) Trusts, Health Boards and
Universities in order to facilitate translational (or “bench-to-
bedside”) research. As well as conducting early-phase studies,
ECMC representatives advise on research conduct and policy and
contribute to Department of Health and Social Care (DHSC) and
National Institute of Health Research (NIHR) steering and advisory
committees. At the ECMC Annual Network meeting in 2017 it
became clear that, although stakeholders acknowledged that CID
trials could accelerate drug development, few had expertise in
conducting them. Workshops were held in February and June
2018 with relevant stakeholders from academia, funding bodies,
regulators, health technology assessment (HTA) and industry
including representatives from The Association of the British
Pharmaceutical Industry (ABPI), BioIndustry Association (BIA),
Cancer Research UK (CRUK), DHSC, Cardiff and Vale University
Health Board, NHS Greater Glasgow and Clyde, Health Research
Authority (HRA), Medicines and Healthcare products Regulatory
Agency (MHRA), Clinical Trial Units (CTUs), Research Ethics
Committees (RECs), academic institutions, National Institute of
Health and Care Excellence (NICE), National Institute of Health
Research (NIHR), patients, Independent Cancer Patient Voices
(ICPV), researchers and NHS Trust Research and Development
(R&D) Managers from across the UK (the ECMC CID working
group). A writing workshop focused upon the most challenging
aspects of CID trials in order to provide recommendations on how
Table 1. Types of CID trials.
(i) Evaluation of one
experimental treatment (E),
common to all cohorts
(ii) Comparative evaluation of
multiple experimental
treatments (E1, E2, E3, …),
common to all cohorts
(iii) Non-comparative evaluation of
single (E) or multiple experimental
treatments (E1, E2, E3, …), each
specific for a biomarker-
defined cohort
Population
defined by
a single
disease
No biomarker i.e., single
cohort defined by
disease
“Standard” RCT investigating E
vs Control (C)
Multi-arm multistage (MAMS)
design comparing E1 vs E2 vs E3
etc. vs C
e.g., STAMPEDE29
Not relevant for trials with no biomarker
Population stratified by
single biomarker (B) i.e.,
two cohorts: B+ and B−
Stratified biomarker design
investigating E vs C within
each cohort
Biomarker stratified MAMS design
comparing E1 vs E2 vs E3 etc. vs C
separately in B+ and B−
Biomarker strategy design evaluating
the strategy of using E in B+ cohort and
C in B− cohort
Population stratified by
multiple biomarkers
i.e., biomarkers B1+ ,
B2+ , B3+… and B-
Stratified biomarker design
investigating E vs C within
each cohort
Biomarker stratified MAMS design
comparing E1 vs E2 vs E3 etc. vs C
within each biomarker cohort
e.g., I-SPY2,30 BATTLE31
Umbrella trial evaluating treatment E1 in
B1+ cohort, E2 in B2+ cohort etc.
Experimental treatments could be
allocated to a basket of biomarker
cohorts e.g., PROFILE 1001,14 FOCUS4,32
National Lung Matrix Trial21
Population
defined by
multiple
diseases
No biomarker i.e.,
multiple cohorts defined
only by disease
Stratified RCT investigating E
vs C across a basket of
disease types
Stratified MAMS design
comparing E1 vs E2 vs E3 etc. vs C
across a basket of disease types
Not relevant for trials without
biomarkers
Population stratified by
single biomarker i.e.,
two cohorts B+ and B-
within each disease
Stratified biomarker design
investigating E vs C within
each biomarker cohort across
a basket of disease types
Stratified MAMS design
comparing E1 vs E2 vs E3 etc. vs C
separately in B+ and B− across a
basket of disease types
Biomarker strategy design evaluating
the strategy of using E in B+ cohort and
C in B− cohort across a basket of
disease types
Population stratified by
multiple biomarkers i.e.,
biomarkers B1+ , B2+ ,
B3+ , … and B- within
each disease
Stratified biomarker design
investigating E vs C within
each biomarker cohort across
a basket of disease types
Stratified MAMS design
comparing E1 vs E2 vs E3 etc. vs C
within each biomarker cohort
across a basket of disease types
Umbrella trial evaluating treatment E1 in
B1+ cohort, E2 in B2+ cohort etc.
across a basket of disease types e.g.,
NCI-MATCH33
(i) Descriptions specify the comparison of experimental arms to a control arm C, but designs can include experimental arms that would be compared to
historical controls; (ii) all designs described that include multiple cohorts or multiple experimental treatments can also be dynamic platform trials; (iii) all
designs can be adaptive and incorporate seamless transition from one phase to the next
Examples of studies shown in Bold type
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they could be addressed. While it was agreed that most aspects of
designing and conducting CID trials are similar to those of any
clinical trial, CID trials present unique challenges at specific points
along the clinical trial pathway (see Fig. 1). A summary of the ten
consensus recommendations are provided in Table 2.
CONSENSUS RECOMMENDATIONS
Trial planning and design—early stakeholder engagement
Recommendation 1: trial planning and design—engagement with
regulators
Investigators/sponsors should arrange a joint meeting with
regulators, HTA bodies and other key stakeholders as early as
possible before or during the trial design to guide and shape the
delivery of the CID trial, especially if accelerated (e.g., conditional)
approval is likely to be applied for.
As with any clinical trial involving an Investigational Medicinal
Product (IMP), approval of a clinical trial authorisation (CTA)
application is required before a CID trial can be conducted. In
Europe, this is obtained from a regulatory “Competent Authority”,
for example, the MHRA in the UK or the HPRA in Ireland.
To maximise the chance of a successful application, sponsors of
CID trials should arrange an advice meeting at an early-stage of
protocol development with both the Competent Authority and
other interested parties, such as health technology assessment
(HTA) bodies, NICE or SMC. Commercial sponsors may also seek
advice from the EMA and EUNetHTA. A joint meeting of this type
has the advantage of ensuring that the objectives and design of
the study meet the requirements of all parties (i.e., demonstrate a
positive risk/benefit balance for the IMP as well as its clinical and
cost-effectiveness) and are appropriate to support CTA approval as
well as future marketing authorisation and reimbursement
decisions. At these meetings, the overarching trial aims and
specific aspects of the study protocol or development pro-
gramme, the selection of the patient population, the choice of
comparator and the endpoints can be addressed.
These discussions are particularly relevant for IMPs that may be
destined for accelerated (e.g., conditional) marketing authorisa-
tion. As the accelerated approval pathway is a relatively novel
concept in UK (and in the EU), the choice of surrogate endpoints,
for example, must be carefully considered. In particular, as to
whether the surrogates (for example, rate of pathological
complete response) are likely to adequately predict clinical
outcomes relevant to NICE and most HTAs in Europe, such as
overall survival. This is particularly important if they are to be
evaluated later, once marketing authorisation has been obtained.
Of note, basket trials should be comparative and randomised
whenever possible to support reimbursement decisions with the
choice of active comparator ideally reflecting clinical practice.
Non-comparative basket studies (consisting of several single arm
studies) should only be conducted when comparative trials
are not feasible, and a justification of this design should be
documented.
Even when expedited approval is not anticipated, the over-
arching aim of these advice meetings is to gain mutual
understanding on how the study design will enable the trial
hypothesis to be tested effectively and thereby help towards
securing trial and marketing approval. By working together in
this way, regulators, HTA, sponsors and investigators can refine
their knowledge and understanding of how to safely conduct
successful CID trials (for examples of meeting options in the
UK see Table 3). It is important that any learning and best
practice acquired are then shared between relevant regulatory
authorities and academic communities in the UK, EU and US to
further support the body of evidence around this type of clinical
research.
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2) Protocol
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Fig. 1 CID Trial Pathway (adapted from the NIHR Clinical Trials Toolkit Routemap28) showing the stages of clinical trial development leading to
licensing and approval (blue). Stages shown in red correspond to Consensus Recommendations defined in this paper that are of particular
relevance to CID trials.
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Protocol development
Recommendation 2: protocol development
The protocol should identify and briefly describe any possible
future modifications (such as additional study arms) to reduce the
likelihood of major amendments. Events defining the end of trial
must be included.
Structuring a protocol. CID trials can be presented as a single trial
with a single protocol (e.g., core/master protocol plus individual
parts/modules/appendices) or as separate trials, with the master/
core protocol submitted each time, but with additional modules.
It is essential that all parts of a CID protocol are clearly worded to
enable easy navigation between them. Although there is no
standardised CID protocol, modifiable templates are available in
the UK from the HRA.18
Defining the trial hypothesis and primary objectives. A CTA
application is more likely to be successful if the overarching trial
hypothesis is clearly defined and the primary study objective(s)
are designed to answer it in a specific, timely and scientifically
valid way. This will enable clarification of when an amendment
or a new trial is required to address an incoming research question
and reduce the likelihood of generating results that are
insufficient to meet regulatory requirements.
Identifying adaptations. Due to the duration and complexity of
CID trials, it is likely that amendments to its design or delivery will
be required during its course. As amendments are costly and time-
consuming, they can, to some extent, be mitigated by defining
clear parameters in the initial application, such as anticipated
future modifications. These include, for example, stating which
future patient populations are likely be evaluated, the number of
IMPs or future study arms that are likely to be added and the
criteria to decide this, how dosage alterations will be decided and
how unexpected toxicities might alter the conduct and design of
the trial. In addition, a plan should be in place to oversee and use
emerging outcome data, to decide which external developments
could alter the protocol and how and when (and with what
evidence) biomarker selection criteria could change. If details are
unknown at the time of the initial application, for example, which
future dosing regimens will be selected, all available data should
be included with the caveat that a later amendment will be filed
to provide more information. A sponsor wishing to add new arms
or IMPs to an ongoing trial should seek advice from the regulators
prior to submitting an amendment to determine if it is considered
substantial or non-substantial; if this modification was predicted in
the original protocol, it is more likely to be defined as being non-
substantial.
Appropriate resource should be available for both central
coordination and study site/per patient costs in CID trials. Over
time, changes in the approved use of agents and standard of care
agents can occur, so consideration should be given to how such
changes will be managed during the life of the trial and the
costing model should reflect this. Upfront costs should adequately
meet the administrative burden to set up CID studies, as well as to
manage potential multiple amendments and the inclusion of
additional study arms.
Data and databases. The data in CID trials are often complex,
obtained from multiple sources (e.g., clinical, laboratory/biomar-
ker, imaging and safety) and used for decision-making at many
points in the study to determine whether particular cohorts will
continue. Therefore, the protocol must include details and a clear
definition of the minimum data required for such decisions.
IT systems will need to be designed, tested and validated to
appropriately manage the entry and registration of patients as
Table 2. Summary of consensus recommendations.
Recommendation 1—Trial Planning and Design – Engagement with Regulators
Investigators/sponsors should arrange a joint meeting with regulators, HTA bodies and other key stakeholders as early as possible before or during
the trial design to guide and shape the delivery of the CID trial, especially if accelerated (e.g., conditional) approval is likely to be applied for.
Recommendation 2—Protocol Development
The protocol should identify and briefly describe any possible future modifications (such as additional study arms) to reduce the likelihood of
substantial amendments. Events defining the end of trial must be included.
Recommendation 3—Patients and public involvement (PPI)
Patients and the public may require specific training, support, and perhaps also accreditation, in order to review and/or manage CID trials.
Recommendation 4—Patient Facing Documentation
A practical approach using three-part patient information should be provided; comprising an invitation document, a study arm-specific document
and a handbook. Multimedia can be considered for some or all of these documents.
Recommendation 5 —Statistical Considerations
Experienced and detailed statistical input is required to provide an overarching statistical design with flexibility to incorporate individual variations for
different treatments, diseases and molecular characteristics. Having a range of expertise within the oversight committee will ensure timely and
appropriate responses to the frequent analyses produced.
Recommendation 6—Defining Leadership and Oversight
A Trial Management Group with experience of CID trials should be convened to oversee the study. New Chief Investigators (CIs) and/or Principal
Investigators (PIs) should be appointed during the study as its requirements evolve.
Recommendation 7—Dissemination of Results
When a research question is answered, or a study arm is completed, timely reporting of trial data at these pre-specified time points should be
supported as best practice.
Recommendation 8 —Staff Training
Training in complex trial methodologies should be included in the undergraduate and post-graduate training curricula of relevant health care
professionals in order to ensure appropriate resources are in place to deliver CID trials.
Recommendation 9 —Approval and Reimbursement Decisions
Accelerated-access initiatives are vital in ensuring CID trial findings are rapidly transitioned to regulatory approval, reimbursement decisions and
adoption into clinical practice.
Recommendation 10 —Evaluating the impact on public health
Impact analyses should be conducted on all CID trials to ensure they deliver on their promise to provide timely access to these medicines in clinical
practice without compromising patient safety.
Effective delivery of Complex Innovative Design (CID) cancer. . .
SP. Blagden et al.
4
well as facilitate the collation of data, monitoring and reporting of
progress throughout the trial. Flexibility of the system will be
important where treatment schedules, cohorts and interventions
are likely to change.
Contracts. CID trials may require the involvement of multiple
parties: funders, study sites, IMP providers, laboratories and third-
party service providers. Planning and resourcing for this aspect of
set-up should also reflect the number and range of contracts
which will be required, as well as the timelines for negotiation and
agreement.
Risk assessment and monitoring. Risk assessment is particularly
important for CID trials, and should include consideration of
financial and operational risks alongside the trial management
activities required to mitigate them. Early consideration of the
level of source data verification (SDV) required should feature in
trial planning, in which data will be used for decision points and
for regulatory registration packages. Feasibility of the desired SDV
levels should be considered too, as some sites may be unable
to host the volume or frequency of monitoring that is required.
Risk-based monitoring is a data-driven approach which can lead
to improvement in the efficiency of monitoring while preserving
data quality.19 This approach has been endorsed by the EMA, and
is particularly suited to CID trials given their complexity.9
Trial management support. Coordination of such trials requires
expert trial and programme management. Trial management is
usually designed to meet the requirements of distinct sequential
study phases: set-up, recruitment, patient follow-up and subse-
quent analysis and reporting. However, CID trials may have
multiple cohorts at different stages open at any given time,
complicating the expertise and time required to coordinate
activity across multiple phases, protocols/cohorts and with third
parties in order to maintain compliance and communication.
Additional resource may be required to ensure that communica-
tions are adequately managed, input from multiple parties is
coordinated and the relevant information and data are made
available at the key discussion and decision time points.
Defining the end of the trial. Although CID trials are designed to
be flexible, a clear trial end needs to be specified, e.g., a maximum
study duration, a maximum number of arms or events that
define the end of each study arm. This is to prevent the
establishment of an endless study, with numerous additional
arms or IMP combinations that were not considered in the original
Table 3. UK options for obtaining advice.
Type of advice Scope
MHRA Regulatory scientific advice https://www.gov.uk/guidance/
medicines-get-scientific-advice-from-mhra
The questions should address specific scientific issues on quality, non-
clinical, clinical or regulatory aspects.
MHRA Broader Scope advice https://www.gov.uk/guidance/medicines-
get-scientific-advice-from-mhra
A broader scope meeting is not a product-specific request, but a broader
discussion.
Examples include:
• practical issues of study design, management and analysis
• general approaches to product development
• overall product development plans where there are very broad issues that
may go beyond what can be discussed at a routine scientific advice
meeting
NICE scientific advice (and parallel advice with the MHRA): https://www.
nice.org.uk/about/what-we-do/life-sciences/scientific-advice
Contact: https://www.snapsurveys.com/wh/s.asp?k=152629077520
NICE offers fee-based consultancy service to developers of pharmaceuticals
or biopharmaceuticals. NICE scientific advice helps develop evidence that
demonstrates the value of investigational medicinal products (IMP). NICE
provide detailed advice on clinical (population, interventions, comparators
and outcomes), economic and evidence generation plans, help to integrate
cost-effectiveness considerations into evidence generation plans.
MHRA scientific advice (and parallel advice with NICE):
https://www.gov.uk/guidance/medicines-get-scientific-advice-from-
mhra
At these meetings clinical trials sponsors will be able to discuss clinical
study design that can satisfy regulatory and NICE requirements. Sponsors
can also get optional input from the Clinical Practice Research Datalink
(CPRD).
MHRA regulatory advice
CTU.AdviceMeetings@mhra.gov.uk
This service provides information, advice and guidance that clarifies UK and
EU regulatory requirements. This service is often, but not exclusively,
utilised by academic Sponsors.
MHRA Innovation Office https://www.gov.uk/government/groups/
mhra-innovation-office
The MHRA Innovation Office is open to queries about innovation in
medicines, medical devices and novel manufacturing processes—
particularly those that challenge the current regulatory framework. The
office provides access to world-class knowledge, expertise and experience
from specialists across MHRA (including the Inspectorate, Enforcement and
Standards Unit), CPRD (Clinical Practice Research Datalink) and NIBSC
(National Institute for Biological Standards and Controls). Experts from the
Health Research Authority and Human Tissue Authority can also be
requested.
MHRA CTU Help line clintrialhelpline@mhra.gov.uk It is possible to contact the CTU directly for specific queries about clinical
trials or aspects that do not require an advice meeting.
HRA Queries
HRA.Queries@nhs.net
General queries on the health research process, including research ethics.
IRAS http://www.myresearchproject.org.uk/help Application portal for research approvals (MHRA, HRA, REC)
NHS Research Scotland http://www.nhsresearchscotland.org.uk/
enquiries@nrs.org.uk
Support in Scotland
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trial design. Planning adaptations require a rigorous science peer
review, and the review cycle of funding applications needs to be
taken into consideration. It is important to discuss with the
relevant funding bodies how this review process can be managed
efficiently to avoid undue delays for adaptations. In addition, any
change to the end of trial, for whatever reason, should be notified
as a substantial amendment, with prior regulatory discussions
recommended.
Patient and public involvement (PPI)
Recommendation 3: patient and public involvement
Patients and the public may require specific training, support, and
perhaps also accreditation, in order to review and/or manage CID
trials.
As with all trials, PPI should be embedded in all stages of the
process from trial planning and design to dissemination of the
results. It is important to ensure the wording of all trial
documentation is not unnecessarily technical and is suitable for
lay readers. The complicated nature of CID trials and the time
commitment required to review the CID trial documents needs to
be recognised, and could be met in an accreditation process
whereby patients and the public involved in the review and
conduct of CID trials are given specific and appropriate training
and support.
PPI groups should be invited to review and comment on
participant information sheets, to ensure “information overload” is
avoided, and the protocol itself to ensure the eligibility criteria
are justified and are not unnecessarily discriminatory. This is
particularly relevant for protocols in which specific age or
performance status cut-offs have been applied or certain
comorbidities or past medical conditions are excluded without
scientific justification. For disease-specific studies, PPI engagement
can provide information about the impact of a disease on the
patient’s daily life, from which the appropriate patient reported
outcome measures (PROMs) can be selected. Evidence of this
involvement should be recorded in trial documentation.
Patient-facing documentation
Recommendation 4: patient-facing documentation
A practical and encouraging approach using three-part patient
information should be provided comprising an invitation docu-
ment, a study arm-specific document and a handbook. Multimedia
can be considered for some or all of these documents.
CID trials are invariably complex, and a single patient information
sheet is likely to either be too long and complicated, containing
non-applicable information, or too brief to be helpful. One
suggested approach is for patient-facing documentation for CID
trials to be broken down into three documents.
Document 1: an invitation document. This should be an
introduction to the research as a whole, possibly in the form of
an invitation letter outlining the overall objectives of the trial. This
should be less than two pages in length. If the patient has yet to
be allocated to an arm it should describe how this will be done:
i.e., randomisation.
Document 2: a study arm-specific document. This should provide
the participant with enough information to enable them to
understand what taking part will entail specifically for them. It
should include a clear study visit schedule, a description of the
drugs to be administered, procedures and tests to be conducted, a
list of the main risks and any prohibited activities, foods or
medications. It should be no more than four pages long, and
ideally include a summary flow chart.
Document 3: a participant handbook. This should describe the
technical and practical details of taking part in the trial, for
example, the expenses to be paid, insurance and complaint
procedures, legal details such as data protection regulations and
information regarding the storage and analyses of tissue biopsies,
protection and sharing of the personal data. This document
should contain a comprehensive contents page, and be clearly
indexed. The handbook should ideally not require amendment as
the information contained is unlikely to change during the course
of the CID trial. Formats other than the written word should be
considered, such as videos and multimedia which have been
shown to improve both patient and researcher satisfaction. Within
the UK, the HRA and MHRA produced a joint statement in
September 2018 endorsing the use of multimedia and eConsent,
which removed the requirement for “wet signatures” for
regulatory compliance inspection purposes.20
Statistical considerations
Recommendation 5: statistical considerations
Experienced and detailed statistical input is required to provide
an overarching statistical design with flexibility to incorporate
individual variations for different treatments, diseases and
molecular characteristics. Having a range of expertise within the
oversight committee will ensure timely and appropriate responses
to the frequent analyses produced.
Statistical requirements vary by the type of CID trial. In umbrella
trials, in which different experimental treatments in different
biomarker subgroups within the same protocol are evaluated,
an overarching statistical design that is common to all treatment
arms can be deployed.7 For example, the National Lung Matrix
Trial uses a Bayesian adaptive design with a common set of
outcome measures, but different primary outcomes and
clinically relevant thresholds specified for different biomarker
cohorts.21 With different biomarkers having different prevalences,
rates of recruitment to each cohort can vary dramatically requiring
interim analyses at multiple time points. This requires close
working with statistical teams and regular updates to oversight
committees. Umbrella trials provide a unique opportunity to
evaluate treatments for rare biomarker cohorts that would not
otherwise be possible, but it may not be feasible to reach a
statistically optimal sample size, leaving a greater level of
uncertainty.
In basket trials, where a single treatment is being investigated
across multiple tumour types, the central statistical approach is to
“borrow information” i.e., the analysis of the treatment effect in
any individual disease cohort accounts for the effects that are
observed in the other parallel cohorts. Various methods have been
proposed to do this. The main challenge is determining the level
of exchangeability of information across disease types that is
biologically valid. CID trials that aim to compare multiple
experimental treatments either against each other or a common
control arm typically use a multi-arm multistage (MAMS) design
allowing interim statistical analyses to drop arms that do not show
promise and, if new arms are added within an ongoing platform
trial, then statistical comparisons can only be made against
contemporaneous patients in other arms.
CID trials are often adaptive, allowing interim trial data to be
used to make changes to the design as it proceeds, but such
adaptations must be planned upfront and adjusted for within the
statistical analysis. The complexity of designs may be more readily
addressed by using a Bayesian approach to analyses, which can
provide more flexibility and intuitive decision-making than within
a hypothesis-testing frequentist framework, but requires complex
computer simulations to determine necessary sample sizes and
operating characteristics of the design.
The heavier statistical workload to deliver CID trials should not
be underestimated when considering the resources required.
Such trials often involve more complex statistical methodology
and require specialist expertise. Once the trial is running, the
availability and responsiveness of the statistical team are critical to
the delivery and reporting of the study.
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Trial conduct and delivery considerations—leadership and
management of responsibilities and expectations
Recommendation 6: defining leadership and oversight
A Trial Management Group with experience of CID trials should be
convened to oversee the study. New Chief Investigators (CIs) and/
or Principal Investigators (PIs) should be appointed during the
study as its requirements evolve.
As with all studies, in CID trials the sponsor is ultimately
responsible for the safety of the trial participants and the integrity
of the study, but may wish to agree a “level of understanding”
between themselves, the investigators and the organisation
responsible for conduction of the trial (typically a Clinical Trials
Unit (CTU) or a Contract Research Organisation (CRO)) to delegate
some responsibilities.
Whilst a conventional trial may answer one primary research
question and have a single CI, CID trials present a number of
research questions during their life course. Therefore, it may
become necessary for CI and PI responsibility to be shared or
transferred between specialists over time. This is particularly the
case for trials across different cancer types and at different stages
of disease where clinicians will have varying levels of sub-
specialisation. Trial protocols and contracts must be adaptable to
accommodate these leadership changes. This also applies to
switching operational and statistical specialists if the design
moves from early into later-phase periods of research. The Trial
Management Group (TMG) should include members with
experience of CID trials, both in terms of scientific design and
delivery. The members also need to appreciate that the level of
time commitment is likely to be considerably greater than for a
conventional trial. The TMG should be prepared to adapt its
structure and membership to engage the most suitable expertise
at different stages of the programme of work. Moreover, as
alterations are introduced to the trial, there may be a need to
introduce additional oversight or amend the remit of existing
oversight committees, for example, involving Independent Data
Monitoring Committees and Trial Steering Committees. An
important remit of the Steering Committee is to carefully consider
the preclinical and clinical evidence generated around investiga-
tional products used in the study alongside that generated from
contemporaneous trials using similar products (for example, with
the same mechanism of action or sharing similar pharmacody-
namic properties). This prevents duplication of futile therapeutic
strategies and inefficient use of resources, both being over-riding
principles of CID trials.
Reporting and publishing results
Recommendation 7: dissemination of results
When a research question is answered, or a study arm is
completed, timely reporting of trial data at pre-specified time
points should be supported as best practice.
For many CID trials, the legally defined “end of trial” occurs when
all the multiple research questions have been answered, and there
are no further data collections or amendments required. However,
for a CID trial that is being sequentially adapted by adding or
dropping new parallel investigational arms, the primary endpoint
in some arms may be reached months or even years before the full
trial is completed and the optimal reporting time may be unclear.
There may be restrictions on the timing of study reporting, such as
to protect the blinding of study data, avoid introducing biases or
false discoveries and preserve confidence in the validity of the
overall trial results. In addition, many CID trials are conducted
under commercial or academic–commercial partnerships with
commercial sensitivities to be considered. In some circumstances,
full release of data on the biomarker characteristics of responding
patients could be of value for the commercial development of an
agent. However, to maintain the overall trial integrity, a more
restricted interval release of specific outcome data to trial
investigators and collaborating companies is required.
Importantly, there is now a legal obligation in the EU and in the
US to report both negative and positive clinical trial results either
in EudraCT or in clinicaltrials.gov. within a specific time of study
closure. Although there is no regulatory mandate to report interim
trial data or make the results of completed arms of a CID trial
available on public trial registries until the whole trial is
completed, the prompt reporting of the results as they are
obtained minimises the risk of duplication of effort whilst enabling
early dissemination of important findings into the community. It is
our recommendation that reporting of trial data at robust and pre-
specified time points when scientifically and clinically relevant
should be supported as best practice and the most appropriate
timing of data release must be predefined in the protocol. It will
be crucial to ensure this practice extends beyond scientific
publication and includes dissemination to trial participants and
other interested groups and communities. In addition, a clear
publication policy should be defined at the start of the trial and
specified in the protocol. Many CID trials may need to publish
under a collective consortium and allowances for this should be
made by journals and publishers.
Evaluating the impact on the trial team and the need for training
Recommendation 8: staff training
Training in complex trial methodologies should be included in the
undergraduate and post-graduate training curricula for relevant
health care professionals in order to ensure appropriate resources
are in place to deliver CID trials.
The extended duration of CID trials, the necessity to adapt the trial
to emerging data and the inclusion of later-phase and site-specific
cohorts means that CID trials require intense involvement from
investigators. This requires a high level of PI and trial committee
oversight, not only to review and assess their own patients but to
participate in regular conference calls/communication with other
centres and trial sponsors. They should maintain detailed and up-
to-date knowledge of the study accrual across the investigative
centres and make decisions based on, often quite preliminary,
data. It is important that centres wishing to conduct CID trials
recognise the benefit to their patients of these types of trial and
ensure there is sufficient time and support for investigators to
deliver them safely and that investigators are fully appraised of
their roles and responsibilities beforehand.
CID trials provide important opportunities for more junior
researchers to learn about the delivery of clinical trials. Training
in innovative trial methodologies should be included into the
curriculum of medical, nursing and pharmacology students. Once
qualified, health professionals should have access to appropriate
continued or higher education about clinical trials. Masters courses
have already proven successful in training trialists. Conferences
with the specific aim of educating doctors in trial conduct also
provide an important teaching forum for the next generation as,
currently, early-phase trial experience is not mandated within the
oncology training curriculum. Furthermore, the UK Government’s
Life Sciences Sector Deal 2 has committed to delivering a skills
programme to embed expert understanding of how innovative
trials can be run across the NHS.11 The NIHR Clinical Research
Network plans to deliver e-learning courses, designed to increase
awareness and understanding of innovative trial designs, supple-
mented with targeted learning for specific groups.
Fast-tracking CID trials to the clinic
Recommendation 9: approval and reimbursement decision
Accelerated-access initiatives are vital in ensuring CID trial findings
are rapidly transitioned to regulatory approval, reimbursement
decisions and adoption into clinical practice.
The faster transition of new medicines into clinical practice is not
solely achieved by speeding up clinical trials but also requires a
conducive legislative environment. In normal circumstances, once
a medicine has undergone clinical evaluation, it must receive
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marketing authorisation and then be appraised by national Health
Technology Assessors before becoming available to patients. The
“21st Century Cures Act” was passed in the USA to enable the FDA
to speed up this pathway for agents showing early clinical promise
by implementing priority review, breakthrough therapy, acceler-
ated approval and fast-track approval status.22 Sponsors are thus
able to seek “breakthrough status” on the basis of surrogate or
intermediate clinical endpoints (rather than overall survival) as
indicators of clinical promise and apply for fast-track designation.
In a similar vein in the EU, following the EMA’s PRIME scheme,23
accelerated-access initiatives have been launched to reduce the
timeframe to review applications and grant a conditional market-
ing authorisation. Similarly, the UK government’s Accelerated
Access Collaborative (AAC) confers “transformative designation”
on drugs, diagnostics, medical and digital technologies so they
can enter an Accelerated Access Pathway (AAP).24 In 2019, the
remit of the AAC was expanded to include all UK health
innovation.25 By these mechanisms, a conditional marketing
authorisation is granted to manufacturers provided they fulfil
post-authorisation commitments to address any areas of uncer-
tainty and/or evidence gaps to fully characterise the full risk/
benefit profile of their product. Despite the obvious advantages of
these rapid-access schemes, the early approval of medicines is not
without risk. Some anticancer products that benefited from fast-
tracked approval by the FDA on the basis of surrogate endpoints,
such as overall response rate or duration of response, subse-
quently failed to show adequate confirmatory clinical outcomes or
demonstrated emergent safety concerns. It is therefore essential
that regulators specify the appropriate post-marketing commit-
ments to manufacturers, and that marketing authorisation is
withdrawn if these are not met.26,27
Evaluating the public health impact of CID trials
Recommendation 10: evaluating the impact on public health
Impact analyses should be conducted on CID trials to ensure they
deliver on their promise to provide timely access to these
medicines in clinical practice without compromising patient
safety.
No formal comparisons of CID with traditional studies (randomised
controlled clinical trials) have yet been performed to confirm they
do indeed provide a faster route to clinic. Impact analyses are
therefore required to fully evaluate the effectiveness, speed and
efficiency of CID studies. In addition, ongoing appraisal must be
conducted of the cost and public health consequences of fast-
tracking medicines to patients to ensure they are clinically
advantageous and cost-effective. This also confers greater reliance
on post-authorisation and conditional reimbursement data
collection (e.g., via the Cancer Drugs Fund) based on clinically
relevant clinical endpoints (e.g., overall survival, PROMs) to provide
a fully comprehensive assessment of the risks and benefits of fast-
tracking the development of cancer medicines.
CONCLUSIONS
By using the ECMC network to bring together stakeholders and
share their perspectives, ten consensus recommendations have
been developed to provide a framework of multi-stakeholder
guidance on conducting CID trials. Early involvement from
competent authorities and HTA bodies into the design of these
studies can assure their success and rapid adoption. As the
concept of CID studies is still relatively novel, it is important that
expertise gained from conducting them is shared between
regulatory authorities and academic communities within and
beyond the UK. Furthermore, formal collaborations should be
established between global regulators to disseminate universal
best practice in all aspects of these studies and across
other therapeutic areas. To optimise the utility of these trials,
accelerated approval schemes are in development to fast-track
IMPs showing positive early efficacy signals. Although challen-
ging, CID studies have the potential to facilitate wider and faster
access to treatment innovation, to enhance the therapeutic
options available to cancer patients and to accelerate the
development of treatments that can significantly improve
clinical outcomes.
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Glossary of terms
AAC Accelerated Access Collaborative
AAP Accelerated Access Pathway
ABPI Association of the British Pharmaceutical Industry
BIA BioIndustry Association
CDF Cancer Drugs Fund
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Chief investigator (CI) (a) in relation to a clinical trial conducted at a single
trial site, the investigator for that site, or (b) in
relation to a clinical trial conducted at more than one
trial site, the authorised health care professional,
whether or not he is an investigator at any particular
site, who takes primary responsibility for the conduct
of the trial.
CID Complex Innovative Design
CPRD Clinical Practice Research Datalink
CRO Contract Research Organisation
CRUK Cancer Research UK
CTA Clinical Trial Authorisation
CTU Clinical Trials Unit
DHSC Department of Health and Social Care
ECMC Experimental Cancer Medicine Centre
EMA European Medicines Agency
EUNetHTA European Network for Health Technology
Assessment
FDA US Food and Drug Administration
Funder The body or bodies that fund a research project.
GCP Good Clinical Practice
HPRA Health Products Regulatory Authority
HRA Health Research Authority
HTA Health Technology Assessment
ICPV Independent Cancer Patients’ Voices
IMP Investigational Medicinal Product
Investigational research /
clinical trial
any investigation in human subjects intended to
discover or verify the clinical, pharmacological and/or
other pharmacodynamic effects of one or more
investigational medicinal product(s), and/or to
identify any adverse reactions to one or more
investigational medicinal product(s) and/or to study
absorption, distribution, metabolism and excretion of
one or more investigational medicinal product(s)
with the object of ascertaining its (their) safety and/
or efficacy.
IRAS Integrated Research Application System
MAMS Multi-arm, multi-stage
MHRA Medicines and Healthcare products
Regulatory Agency
NCSLC Non-small cell lung cancer
NHS National Health Service
NICE National Institute for Health and Care Excellence
NIHR National Institute for Health Research
Oversight committee Having responsibility for the scientific management
of the trial.
PD Pharmacodynamics
PK Pharmacokinetics
Patients and service users Recipients of health care, social care or other services
or support provided by or on behalf of health or
social care organisations, such as NHS patients and
social care service users. Includes people receiving
integrated health and social care, e.g. Health and
Social Care (HSC) users in Northern Ireland. Excludes
children’s social care service users in England and
Scotland.
PPI Patient and Public Involvement
Principal Investigator (PI) The lead investigator who is responsible for the local
conduct of the trial at a site and to whom other sub-
investigators and research team members are
accountable.
PROM Patient Reported Outcome Measure
The public The general public. Includes carers, relatives of
patients and service users and healthy volunteers.
Public involvement Working in collaboration with patients, service users
or the public in the design, management, conduct or
dissemination of research.
RCT Randomised Controlled Trial
REC Research Ethics Committee
Research site The organisation with day-to-day responsibility for
the location where a research project is carried out.
Research team The people involved in the conduct of a research
project. There may be different research teams for
the project at different sites.
SDV Source Data Verification
SMC Scottish Medicine Consortium
Sponsor The person or body who takes on ultimate
responsibility for the initiation, management and
financing (or arranging the financing) of a clinical
trial.
TMG Trial Management Group
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